Cannabis & mental health — the knowledge hub

Medical framework and legal regulations in Switzerland

Since the amendment of the law in August two thousand and twenty-two, medical cannabis in Switzerland can be prescribed directly by treating physicians without the need to obtain a time-consuming exceptional authorisation from the Federal Office of Public Health (BAG). This liberalisation facilitates legal access to controlled formulations for patients with chronic conditions or accompanying psychiatric symptoms. Nevertheless, prescribing for psychiatric indications remains a case-by-case decision, as the scientific evidence for many psychiatric conditions is still considered insufficient. Physicians carefully weigh the benefits and risks, such as potential psychological dependence or the exacerbation of underlying conditions, beforehand.

In parallel, scientific pilot trials in various Swiss cities such as Zurich or Basel allow the controlled dispensing of cannabis containing THC for recreational purposes. These studies, conducted under strict conditions set by the Federal Office of Public Health (BAG), also investigate the effects of regulated consumption on the mental well-being of participants. Anyone caught with more than ten grams of THC cannabis outside of these projects or without a medical prescription must expect a fixed penalty under the Narcotics Act (BetmG). Furthermore, a strict zero-tolerance policy applies in road traffic regarding the detection limit of THC in the blood.

• Direct prescribability of medical cannabis by Swiss doctors since August 2022.
• Scientific monitoring of consumption through government-approved pilot projects in Swiss cities.
• Strict limit in road traffic of 1.5 micrograms of THC per litre of blood serum.
• Fixed penalty procedure for possession of small amounts for personal consumption outside of trials.

Neurobiological mechanisms: The endocannabinoid system and the psyche

The body's own endocannabinoid system plays a fundamental role in regulating emotions, stress responses, and cognitive processes in the human brain. Through the interaction of plant-derived cannabinoids with CB1 receptors, which are particularly dense in brain regions such as the hippocampus and the amygdala, the release of neurotransmitters is directly influenced. While tetrahydrocannabinol (THC) acts as a partial activator of these receptors and modulates synaptic signal transmission, cannabidiol (CBD) exhibits a more complex, partly blocking effect. These differing mechanisms of action explain why the two main active compounds of the cannabis plant can exert such contrasting effects on psychological stability and anxiety perception.

Neurobiological research suggests that dysregulation of the endocannabinoid system could correlate with various psychiatric disorders. However, targeted therapeutic intervention faces the challenges of individual variability and the so-called biphasic effect of cannabinoids. This means that low doses often show anxiolytic and calming effects, whereas higher doses can cause the opposite and trigger panic attacks or paranoid states. For clinical practice, this implies that standardised preparations and close medical supervision are essential to minimise undesirable psychological side effects and stabilise therapeutic outcomes.

• High density of CB1 receptors in brain regions regulating anxiety and emotion.
• Biphasic effect: Dose-dependent reversal of positive into negative psychological effects.
• Modulation of key neurotransmitters in the central nervous system by phytocannabinoids.
• Individual differences in receptor distribution complicate universally applicable dosing recommendations.

Harm reduction and risk management in everyday life

For consumers wishing to minimise the risk of psychological distress, the concept of harm reduction is paramount. Since the unregulated black market often offers products with extremely high THC content and minimal CBD levels, the risk of acute anxiety and long-term psychological crises increases significantly. A balanced ratio of the two active compounds is considered by experts to be much better tolerated, as CBD can counteract the psychoactive and potentially anxiety-inducing properties of THC. Anyone who already suffers from pre-existing psychological conditions or has a family predisposition to psychosis should completely abstain from consuming psychoactive substances to avoid serious health consequences.

In addition to choosing the appropriate active ingredient profile, the method of consumption also plays a crucial role in psychological integrity. Vaporising with a vaporiser or oral consumption carry different risk profiles than classic smoking, whereby the delayed onset of action when eating and drinking can easily lead to accidental overdosing. Consumers should also take regular breaks from consumption to prevent the development of tolerance and gradual psychological dependence. At the first signs of depressive moods, persistent lack of drive, or social withdrawal, it is advisable to seek professional help and critically reflect on one's consumption. Counselling centres and medical professionals offer confidential support for this.

• Avoidance of synthetic cannabinoids and extremely high-potency THC strains.
• Use of CBD as a natural modulator to attenuate undesirable THC effects.
• Caution with oral consumption due to the delayed and difficult-to-control effects.
• Regular consumption breaks to prevent tolerance build-up and psychological dependence.

FAQ